Follicum AB (”Follicum”) today announces that the Korean patent office (”KIPO”) has approved the company’s patent application for stimulation of hair growth. With the approval in Korea, patent number 10-1992282, Follicum has a patent protection in Korean up to and including year 2032. The patent protects the company’s peptides in general and for stimulation of […]
Follicum AB (“Follicum” or “company”) today report that the company has had a successful scientific advisory meeting regarding the hair project FOL-005, with the German authority, BfArM. In accordance with the previously announced timetable, Follicum has prepared a background document for scientific advice with the German Medicinces agency BfArM. The meeting discussed which additional toxicity […]
Follicum AB (“Follicum” or “The Company”), a biotechnology company developing new peptide drugs in two areas, hair loss and diabetes, reports today that Dr. Chrysostomi Gialeli has been recruited to a full-time postdoctoral position for 2 years to further investigate the function and mechanism of action of Follicum’s various peptides. The Postdoc position is 100% […]
Follicum AB today announces the establishment of a Scientific Advisory Board in the diabetes field. The purpose is to strengthen knowledge transfer from academic research to clinical application and commercialization. The Board consists of 5 internationally reputable experts with extensive experience in research into diabetes and its complications. – By setting up a Scientific Advisory […]
Follicum has received an official grant of patent from the European Patent Office, EPO regarding the company’s broadened patent application for stimulation of hair growth. The official grant follows the “Intention to Grant” which was communicated on November 21, 2018. With EPO’s grant of patent no. EP 3087999 B1, there is now broad protection for […]
Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years Follicum AB (“Follicum” or “the company”) today announced that the company’s hair loss treatment projects are progressing according to plan and a patent application for an internally developed formulation of FOL-005 has been submitted. The cream formulation is intended to […]
Follicum AB (“Follicum” or “the company”), a biotech company focusing on research and development of peptide-based drugs, today reports that a drug candidate has been selected for the treatment of diabetes and protection of beta cells. The drug candidate has shown unique effects in both in vitro and in vivo-models, including diabetes-related complications. The drug […]
Follicum AB (“Follicum” or “company”) today reports results for lead candidate FOL-005 in an in vivo-model for hair growth. The study examined hair growth in test animals after treatment with the new creamlike topical formulation of FOL-005 at three different doses. Applied once a day and after about one week of treatment, growth of new […]
Follicum AB (“Follicum” or “Company”), a biotech company developing new peptide drugs in two areas, hair loss and diabetes, today reports that a collaboration agreement with the Centre for Skin Sciences (CSS) at University of Bradford, UK, has been signed. The aim is to combine in vitro experiments with the use of bioinformatics data mining […]
Follicum AB (“Follicum” or “Company”), a biotech company developing new peptide drugs in two areas, hair loss and diabetes, today reports that a full-time post-doc has been awarded to the diabetes project for 2 years. The aim with the project is to perform advanced experiments to further investigate the action of Follicum’s different peptide classes. […]